Market News (Page 25) - TendieTensor

Market News Page 25 of 281 • 7,014 articles

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Not Specified

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

01/06/2026 08:00 AM • CG Oncology announced that its Chairman & CEO Arthur Kuan and President & COO Ambaw Bellete will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The company is a late-stage clinical biopharmaceutical firm developing bladder-sparing therapeutics for bladder cancer patients, with recent data showing promising efficacy rates for its lead candidate cretostimogene grenadenorepvec in non-muscle invasive bladder cancer.

AAPL - Thiel significantly increased holdings by purchasing 79,181 shares, showing confidence in the company's future
CGON - The company is presenting at a major healthcare conference and has announced promising clinical data showing high efficacy rates (95.7% at 3-months, 84.6% at 6-months, 80.4% at 9-months) for its lead therapeutic candidate in high-risk bladder cancer patients, indicating progress in late-stage development.

#bladder cancer #immunotherapy #clinical trial #J.P. Morgan Healthcare Conference #non-muscle invasive bladder cancer #cretostimogene grenadenorepvec

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

GlobeNewswire Inc. • Na

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

01/06/2026 08:00 AM • Mdxhealth announced a collaboration with the University of Oxford to initiate Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial, the world's largest randomized clinical trial for localized prostate cancer treatment. This study aims to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, potentially impacting clinical practice guidelines and payer coverage.

TSLA - Thiel dramatically reduced his Tesla holdings from 272,613 to 65,000 shares, indicating reduced confidence
MDXH - The company is advancing its GPS test through validation in the world's largest randomized prostate cancer trial, which could establish clinical credibility, influence treatment guidelines, and expand payer coverage. This represents significant progress in precision diagnostics and market positioning.

#prostate cancer diagnostics #genomic testing #clinical trial #precision medicine #GPS test #ProtecT trial #active surveillance

NuCana Appoints Theresa Bruce as Chief Operating Officer

GlobeNewswire Inc. • Nucana Plc

NuCana Appoints Theresa Bruce as Chief Operating Officer

01/06/2026 08:00 AM • NuCana plc announced the appointment of Theresa Bruce as Chief Operating Officer effective January 1, 2026. Bruce brings over 25 years of experience in oncology R&D and clinical operations. The appointment comes as NuCana plans to advance its pipeline with anticipated data readouts in 2026 for NUC-7738 and further characterization of NUC-3373, with cash runway extending into 2029.

NCNA - The appointment of an experienced COO with 25+ years in oncology R&D signals organizational strengthening and confidence in advancing the pipeline. The company has extended cash runway into 2029 and multiple anticipated data readouts planned for 2026, indicating progress and financial stability.

#Chief Operating Officer appointment #Theresa Bruce #NUC-7738 #NUC-3373 #clinical development #cancer therapy #Phase 1/2 study #melanoma #ProTide technology

Roadzen Announces Major Strategic Acquisition of AI-Powered Vehicle Repair Platform VehicleCare at CES 2026; Transaction Consideration Values Standalone India Business at ~$277 Million

Benzinga • Globe Newswire

Roadzen Announces Major Strategic Acquisition of AI-Powered Vehicle Repair Platform VehicleCare at CES 2026; Transaction Consideration Values Standalone India Business at ~$277 Million

01/06/2026 08:00 AM • Roadzen Inc. (NASDAQ: RDZN) announced the acquisition of VehicleCare, an AI-powered vehicle repair platform, for approximately $277 million in stock. The deal values Roadzen's India business at a 50% premium to its current public market price with no dilution to the parent company. VehicleCare is expected to contribute $10 million in revenue post-closing and will enable Roadzen to offer end-to-end claims management from digital decisioning to physical repair execution.

RDZN - The acquisition expands Roadzen's capabilities into repair execution, creating a full-stack claims operating system. The deal values the India subsidiary at a significant 50% premium to current market price, demonstrates investor confidence, and adds $10 million in expected revenue with synergy potential. The structure avoids dilution at the parent company level, which is favorable for existing shareholders.

#acquisition #AI-powered platform #vehicle repair #claims management #India business #workshop aggregation #insurance technology

Hallador Energy Appoints Barbara Sugg, Former CEO of Southwest Power Pool, to Join Board of Directors

GlobeNewswire Inc. • Na

Hallador Energy Appoints Barbara Sugg, Former CEO of Southwest Power Pool, to Join Board of Directors

01/06/2026 08:00 AM • Hallador Energy Company has appointed Barbara Sugg, former President and CEO of Southwest Power Pool, to its Board of Directors effective January 1, 2026, replacing David Hardie who resigned after 35 years. Sugg brings over three decades of energy industry leadership experience, including expertise in grid operations, transmission initiatives, and renewable energy integration.

HNRG - The appointment of an experienced energy industry executive with deep expertise in grid operations, transmission projects, and renewable energy integration strengthens the company's leadership and strategic capabilities. This is presented as a positive development to support the company's long-term growth strategy and asset value maximization.

#board appointment #Barbara Sugg #Southwest Power Pool #energy industry #grid operations #transmission #renewable energy integration

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Na

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

01/06/2026 08:00 AM • Cogent Biosciences announced that CEO Andrew Robbins will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is developing precision therapies for genetically defined diseases, with bezuclastinib as its most advanced program for systemic mastocytosis and gastrointestinal stromal tumors. Recent positive trial results showed a 57-80% objective response rate in advanced systemic mastocytosis patients.

COGT - The company is presenting at a major healthcare conference and has demonstrated positive clinical trial results with high objective response rates (57-80%) for its lead drug bezuclastinib in advanced systemic mastocytosis, indicating strong clinical progress and investor interest.

#bezuclastinib #systemic mastocytosis #precision therapies #KIT D816V mutation #GIST #clinical trial #J.P. Morgan Healthcare Conference

Roper Technologies schedules fourth quarter 2025 financial results conference call

GlobeNewswire Inc. • Na

Roper Technologies schedules fourth quarter 2025 financial results conference call

01/06/2026 08:00 AM • Roper Technologies announced that its fourth quarter 2025 financial results will be released on January 27, 2026, before market open, with a conference call scheduled for 8:00 AM ET the same day. The company is a Nasdaq 100, S&P 500, and Fortune 1000 constituent that operates market-leading vertical software and technology-enabled products businesses.

ROP - The article is a routine earnings announcement with standard procedural information about results release and conference call timing. No material business developments, guidance changes, or performance metrics are disclosed that would indicate positive or negative sentiment. The mention of AI leadership appointments in a separate announcement suggests growth initiatives, but the main article focuses only on administrative details.

#Q4 2025 earnings #financial results #conference call #vertical software #acquisitions #shareholder value

IMTE Announces Receipt of Additional Delisting Determination Letter from Nasdaq

Benzinga • Prnewswire

IMTE Announces Receipt of Additional Delisting Determination Letter from Nasdaq

01/06/2026 07:50 AM • Integrated Media Technology Limited (NASDAQ: IMTE) has received an additional delisting determination letter from Nasdaq for failing to file a Form 6-K interim report for its second quarter. This adds to previous non-compliance issues regarding the failure to timely file its Form 20-F for the year ended December 31, 2024. The company has until January 30, 2026 to demonstrate compliance, with plans to present its views to the Nasdaq Hearings Panel by January 9, 2026.

MSFT - Thiel increased holdings by purchasing 49,000 shares, indicating strategic investment interest
IMTE - The company faces serious regulatory challenges with multiple delisting determination letters from Nasdaq due to failure to file required financial reports (Form 6-K and Form 20-F). The company is at risk of suspension and delisting from the Nasdaq Capital Market, representing a significant threat to its continued public trading status and investor confidence.

#delisting #Nasdaq #Form 6-K #Form 20-F #filing requirements #compliance #interim report

Is Thailand Poised For Economic Acceleration In 2026?

Benzinga • Mighty Wisdom

Is Thailand Poised For Economic Acceleration In 2026?

01/06/2026 07:41 AM • Thailand's economy shows potential for acceleration in 2026 driven by tourism recovery, emerging tech and EV manufacturing sectors, and expanding financial services. Despite structural challenges and global headwinds, the country's diversified growth drivers and supportive policies position it for renewed momentum.

BKKLY - As one of Thailand's largest lenders, Bangkok Bank stands to benefit from rising credit demand across consumer, SME, and corporate segments, plus expanding digital initiatives and regional footprint provide resilience.

#Thailand economy #economic growth 2026 #tourism recovery #electric vehicles #fintech #Southeast Asia #manufacturing #digital economy

Smartkem Signs Proof of Concept Agreement with Global Consumer Electronics Giant for MicroLED Wearables

GlobeNewswire Inc. • Smartkem, Inc.

Smartkem Signs Proof of Concept Agreement with Global Consumer Electronics Giant for MicroLED Wearables

01/06/2026 07:00 AM • Smartkem announced a 12-month paid proof-of-concept agreement with a major consumer electronics company to develop next-generation smart wearables featuring conformable MicroLED displays using Smartkem's organic thin-film transistor (OTFT) technology. The collaboration aims to address key wearables challenges including miniaturization, power consumption, and durability, with potential manufacturing on existing Gen2.5 production lines.

SMTK - The company secured a paid proof-of-concept agreement with a major consumer electronics player, validating its OTFT technology for commercial applications. This represents progression from platform validation to product-level execution in a high-growth market (projected to reach $186 billion by 2030), demonstrating market demand and commercial viability of their technology.

#MicroLED display #organic thin-film transistor (OTFT) #smart wearables #proof-of-concept #semiconductor technology #flexible displays #wearable market growth

Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule candidates targeting major autoimmune indications

GlobeNewswire Inc. • Sitryx Therapeutics

Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule candidates targeting major autoimmune indications

01/06/2026 07:00 AM • Sitryx Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The company is advancing its lead program SYX-5219, a first-in-class oral PKM2 modulator for atopic dermatitis, with Phase 1b trials planned for Q1 2026. Additionally, SYX-1042, an itaconate mimetic, completed Phase 1 studies and is positioned to move to Phase 2 patient efficacy studies in 2026.

LLY - Eli Lilly is mentioned as a specialist investor in Sitryx's funding syndicate, indicating strategic interest in the company's immunology programs. However, this is a passive investment relationship with no direct operational involvement disclosed.

#PKM2 modulator #atopic dermatitis #autoimmune disease #clinical trial #oral therapy #immunology #J.P. Morgan Healthcare Conference

BitMEX Launches Equity Perps for 24/7 Stock Trading

GlobeNewswire Inc. • Bitmex Press

BitMEX Launches Equity Perps for 24/7 Stock Trading

01/06/2026 07:00 AM • BitMEX announced the launch of Equity Perps, a new derivatives product enabling 24/7 trading on major U.S. stocks and equity indices using cryptocurrency as collateral. The product supports up to 20x leverage on assets like Bitcoin and Tether, with initial offerings on stocks including Amazon, Apple, Tesla, Nvidia, and indices like S&P 500 and Nasdaq.

WALpA - Stock price fell 10.88% after disclosing a fraud-related lawsuit against a borrower, indicating potential financial and legal challenges
AMZN - Amazon is mentioned only as one of the available trading instruments on the new Equity Perps platform. The announcement does not contain any company-specific news or developments affecting Amazon itself.

#Equity Perps #derivatives #perpetual swaps #cryptocurrency collateral #24/7 trading #leverage trading #U.S. equities

Plug to Participate in Goldman Sachs Energy, CleanTech & Utilities Conference

GlobeNewswire Inc. • Not Specified

Plug to Participate in Goldman Sachs Energy, CleanTech & Utilities Conference

01/06/2026 07:00 AM • Plug Power Inc. announced its participation in the Goldman Sachs Energy, CleanTech & Utilities conference in Miami, Florida. President and CRO Jose Luis Crespo and VP of Investor Relations Roberto Friedlander will hold one-on-one meetings with institutional investors to discuss the company's strategic priorities in the hydrogen economy.

PLUG - The company is actively engaging with institutional investors at a major financial conference, demonstrating confidence in its strategic direction and commitment to investor dialogue. This proactive investor relations activity typically signals management confidence in the company's trajectory and hydrogen market positioning.

#hydrogen economy #investor relations #conference participation #strategic priorities #institutional investors

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

GlobeNewswire Inc. • Lb Pharmaceuticals, Inc

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

01/06/2026 07:00 AM • LB Pharmaceuticals announced the appointments of Ellen Rose as Senior Vice President of Corporate Affairs and Lindsay Beaupre as Senior Vice President of People and Culture. Both executives bring extensive experience from leading biopharmaceutical and financial services companies. The appointments come as the company advances LB-102, its novel benzamide candidate, into Phase 3 trials for schizophrenia and Phase 2 trials for bipolar depression.

LBRX - The company is strengthening its executive leadership team with experienced hires from reputable organizations (Lyell Immunopharma, Prothena, Johnson & Johnson, Vertex Pharmaceuticals, Immunogen). This demonstrates organizational growth and confidence in advancing LB-102 through critical clinical development phases. The appointments support the company's strategic expansion during a transformative period.

#leadership appointments #corporate affairs #people and culture #LB-102 #schizophrenia #bipolar depression #clinical development #biopharmaceutical

RADCOM to Participate in 28th Annual Needham Growth Conference

Benzinga • Prnewswire

RADCOM to Participate in 28th Annual Needham Growth Conference

01/06/2026 07:00 AM • RADCOM Ltd. (NASDAQ: RDCM) announced that its CEO Benny Eppstein and incoming CFO Hod Cohen will participate in person at the 28th Annual Needham Growth Conference on January 13-14, 2026, in New York City. Management will be available for 1x1 meetings with investors throughout the event.

RDCM - The company is actively engaging with investors at a major industry conference, demonstrating confidence and commitment to investor relations. Leadership participation and availability for meetings indicates positive momentum and willingness to discuss business developments.

#Needham Growth Conference #investor relations #AI Operations #5G network #network observability

P10 Opens New Office in Dubai, Strengthening Capabilities in the Middle East Region

GlobeNewswire Inc. • Na

P10 Opens New Office in Dubai, Strengthening Capabilities in the Middle East Region

01/06/2026 07:00 AM • P10, Inc. (NYSE: PX), a leading private markets solutions provider with over $40 billion in assets under management, announced the opening of a new office in Dubai within the Dubai International Financial Centre (DIFC). The office is licensed by the Dubai Financial Services Authority (DFSA) and represents P10's expansion into the Middle East to support client partnerships across the region. The company views this move as a strategic investment in the region's growth as a major financial hub.

CODIpC - Company is managing a challenging financial situation by providing support for its struggling subsidiary while maintaining operations of other business units
PX - The company is actively expanding its global footprint by opening a new licensed office in a major financial hub (Dubai/DIFC), demonstrating confidence in regional growth and commitment to serving clients in the Middle East. Leadership quotes emphasize optimism about the region's stability and investment opportunities.

#P10 Inc. #Dubai #DIFC #private markets #expansion #Middle East #financial services #assets under management

Lantronix Redefines Integrated Edge Intelligence With AI-Powered Surveillance Ecosystem and Real-Time Video Analytics

GlobeNewswire Inc. • Lantronix Inc.

Lantronix Redefines Integrated Edge Intelligence With AI-Powered Surveillance Ecosystem and Real-Time Video Analytics

01/06/2026 07:00 AM • Lantronix announced the debut of SmartEdge.ai 5G-ready Edge AI Gateway and SmartSwitch.ai PoE+ aggregation switch at CES 2026, forming an integrated platform for real-time video analytics and intelligent connectivity. The solutions leverage Qualcomm's QCS6490 processor and target the rapidly expanding AI surveillance market, projected to grow from $73.8 billion in 2024 to $147.7 billion by 2030.

CODIpB - Company is managing a challenging financial situation by providing support for its struggling subsidiary while maintaining operations of other business units
LTRX - Company is launching innovative AI-powered surveillance products at CES 2026, positioning itself in a high-growth market projected to nearly double by 2030. The announcement highlights new revenue streams, margin expansion opportunities, and strategic partnerships with Qualcomm, demonstrating strong market positioning and growth potential.

#Edge AI #video surveillance #5G connectivity #real-time analytics #SmartEdge.ai #SmartSwitch.ai #IoT solutions #intelligent infrastructure

AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial

Benzinga • Vandana Singh

AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial

01/06/2026 06:43 AM • AstraZeneca announced positive Phase 3 TULIP-SC trial results for Saphnelo (anifrolumab) subcutaneous injection for lupus treatment. The drug showed statistically significant disease activity reduction (56.2% vs 37.1% placebo) with a favorable safety profile. Saphnelo is already approved in 70+ countries and has treated over 40,000 patients globally.

JSPRW - The lawsuit alleges the company made false statements about manufacturing controls, potentially misrepresenting product prospects and increasing risks for clinical trials, which suggests significant corporate governance and transparency issues
AZN - Positive Phase 3 trial results for Saphnelo showing statistically significant and clinically meaningful disease activity reduction compared to placebo, with consistent safety profile. Drug already approved in 70+ countries with 40,000+ patients treated. Stock up 0.58% in premarket trading.

#lupus treatment #Phase 3 trial #Saphnelo #anifrolumab #subcutaneous injection #systemic lupus erythematosus #clinical trial results

12 Oil Stocks Best Placed to Benefit From Venezuela’s New Reality Under Trump

Investing.com • David Wagner

12 Oil Stocks Best Placed to Benefit From Venezuela’s New Reality Under Trump

01/06/2026 06:40 AM • Following the US placing Venezuela under temporary oversight, energy stocks have moved into focus as President Trump signals support for US energy firms to rebuild Venezuela's oil sector. Several US oil stocks rose strongly, with Valero Energy jumping 9.2%, Phillips 66 rising 7.2%, and Chevron gaining over 5%. The article identifies 12 undervalued US oil stocks that may benefit from increased investment opportunities in Venezuela's large oil reserves.

VLO - Stock jumped 9.2% following Venezuela developments, indicating strong market confidence in the company's ability to benefit from rebuilding Venezuela's oil sector

#Venezuela #oil stocks #Trump administration #energy sector #OPEC #oil production #undervalued stocks

Short-Term Skepticism Persists Despite Copper's Explosive Start

Benzinga • Stjepan Kalinic

Short-Term Skepticism Persists Despite Copper's Explosive Start

01/06/2026 06:30 AM • Copper rallied above $13,000/ton to start 2026, with major miners like Southern Copper and Freeport-McMoRan gaining 3-5%. However, analyst firm BMI maintains a cautious 2026 price forecast of $11,000/ton, citing macroeconomic headwinds including US dollar strength and slowing Chinese growth, despite acknowledging long-term structural deficits supporting prices toward $17,000/ton by 2034.

CGTX - Mentioned as previous employer of new CFO, no specific company performance details provided
SCCO - Stock gained 3.83% on copper rally, but sentiment is tempered by analyst concerns about demand slowdown in China and macroeconomic headwinds that could cap upside potential in 2026.

#copper prices #supply disruptions #mining equities #macroeconomic headwinds #energy transition #Chinese demand #structural deficit

Radware Doubles Global Cloud Security Capacity

GlobeNewswire Inc. • Radware

Radware Doubles Global Cloud Security Capacity

01/06/2026 06:00 AM • Radware has doubled its global cloud security service network mitigation capacity from 15 Tbps to 30 Tbps by upgrading all centers with DefensePro® X. The company reported an 85% increase in network DDoS attacks in H1 2025 and expanded its global network to 65 cloud security centers across new locations including Colombia, Peru, India, and Singapore.

ZIONP - Significant financial charge-off of $50 million, stock price decline, and potential legal investigation indicating serious financial and operational issues
RDWR - Radware announced significant capacity expansion (doubling mitigation capability to 30 Tbps), global network expansion to 65 centers, enhanced product capabilities with DefensePro X, and continued industry recognition as a market leader. The company is proactively addressing growing threat landscape demands with infrastructure investments and technological improvements.

#DDoS mitigation #cloud security #DefensePro X #AI-powered protection #HTTPS flood attacks #cybersecurity #network attacks #global expansion

Lithium Argentina Announces 2025 Production Results for Cauchari-Olaroz and Leadership Updates

GlobeNewswire Inc. • Na

Lithium Argentina Announces 2025 Production Results for Cauchari-Olaroz and Leadership Updates

01/06/2026 06:00 AM • Lithium Argentina announced strong 2025 operational results for its Cauchari-Olaroz lithium brine operation, achieving 34,100 tonnes of lithium carbonate production at the high end of guidance with record Q4 output of 9,700 tonnes at 97% nameplate capacity. Cash operating costs fell below $6,000 per tonne, and the company reduced net debt by $26 million in Q4. The company submitted Stage 2 expansion applications for 45,000 tpa capacity and announced leadership promotions, with Alec Meikle becoming President and John Kanellitsas transitioning to Chairman.

LAR - Company achieved high-end production guidance (34,100 tonnes), record Q4 production, reduced operating costs below $6,000/tonne, decreased net debt by $26 million, and maintains strong liquidity over $150 million. Positive leadership changes and advancement of Stage 2 expansion and PPG project demonstrate operational maturity and growth trajectory.

#lithium production #operational results #Cauchari-Olaroz #cost reduction #Stage 2 expansion #RIGI application #leadership changes #Argentina #lithium carbonate

McEwen Inc. and Canadian Gold Corp. Announce Closing of Arrangement

GlobeNewswire Inc. • Mcewen Inc. And Canadian Gold Corp

McEwen Inc. and Canadian Gold Corp. Announce Closing of Arrangement

01/06/2026 06:00 AM • McEwen Inc. has completed its acquisition of Canadian Gold Corp through a statutory plan of arrangement, with Canadian Gold shareholders receiving 0.0225 McEwen shares for each Canadian Gold share held. The combined entity plans to accelerate exploration and development of the Tartan project, advance mine permitting, and publish an updated resource estimate by end of February 2026.

LULU - Highlighted as experiencing difficulties in the current market environment.
MUX - The company successfully completed a strategic acquisition, is expanding its gold asset base with the Tartan project, and has clear near-term catalysts including exploration acceleration, mine engineering, and updated resource estimates. Management is actively pursuing value creation through multiple development projects.

#business combination #acquisition #gold mining #exploration #Tartan project #mine development #shareholder value

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

GlobeNewswire Inc. • Not Specified

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

01/06/2026 06:00 AM • Aclarion announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the CLARITY pivotal trial, bringing the total to four sites with patient enrollments. Seven clinical sites have completed regulatory requirements and are ready to enroll. The company expects initial data readout in Q3 2026 after the first cohort completes 3-month follow-up visits. The trial aims to demonstrate that Nociscan improves surgical outcomes for chronic low back pain beyond the current 54% industry benchmark.

NKE - Mentioned as struggling with footwear and apparel market challenges.
ACON - The company announced significant progress on its pivotal CLARITY trial with enrollment at multiple leading medical centers, hired key commercial personnel to drive expansion, and provided a clear timeline for interim data results. These milestones represent meaningful advancement toward generating clinical evidence and supporting future reimbursement discussions, which are critical value drivers for the company.

#CLARITY trial #Nociscan #chronic low back pain #clinical trial enrollment #patient outcomes #spine surgery #biomarkers #MRI spectroscopy

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

GlobeNewswire Inc. • Na

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

01/06/2026 06:00 AM • Apogee Therapeutics reported positive interim Phase 1b results for zumilokibart (APG777), its anti-IL-13 antibody, in mild-to-moderate asthma patients, demonstrating rapid and durable suppression of FeNO biomarker through 16 weeks with a favorable safety profile. The company also highlighted multiple anticipated 2026 milestones including Phase 2 APEX data readouts in atopic dermatitis and potential Phase 3 initiation by late 2026, with a strong cash position of $913 million supporting operations into H2 2028.

CMG - Noted as experiencing weakness in consumer discretionary spending, particularly in the 25-to-35 demographic.
APGE - Company announced positive interim Phase 1b clinical trial results showing favorable safety profile and robust FeNO suppression in asthma patients. Multiple clinical readouts are anticipated in 2026, the company has strong cash position of $913 million with runway into H2 2028, and there is potential for Phase 3 initiation and 2029 launch of lead candidate. The expansion of zumilokibart beyond dermatology into respiratory indications demonstrates pipeline diversification and validates the 'pipeline-in-a-product' strategy.

#zumilokibart #APG777 #Phase 1b trial #asthma #atopic dermatitis #FeNO suppression #anti-IL-13 antibody #clinical trial results #Phase 3 #2026 milestones